EMBC
Embecta Corp
NASDAQ: EMBC · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$3.90
-57.84% today
Updated 2026-05-05
Market cap
$547.78M
P/E ratio
3.92
P/S ratio
0.51x
EPS (TTM)
$2.36
Dividend yield
6.50%
52W range
$4 – $15
Volume
1.1M
WallStSmart proprietary scores
56
out of 100
Grade: C+
Hold
Investment rating
4.7
Growth
C7.5
Quality
B+7.5
Profitability
B+8.3
Valuation
A5/9
Piotroski F-Score
Moderate
1.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →197 stocks currently score above 75
Price targets
Analyst target
$15.00
+284.62%
12-Month target
$11.09
+184.36%
Intrinsic (DCF)
$46.96
Margin of safety
+78.58%
0 Strong Buy1 Buy2 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $16.60M — positive
+ 78.58% below intrinsic value
+ Debt/equity -2.32x — low leverage
Risks
- Altman Z 1.56 — distress zone
- Revenue declining -0.30% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.13B | $1.12B | $1.12B | $1.08B | $1.08B |
| Net income | $223.60M | $70.40M | $78.30M | $95.40M | $44.10M |
| EPS | — | — | — | — | $2.36 |
| Free cash flow | $388.20M | $41.20M | $19.90M | $182.40M | $16.60M |
| Profit margin | 19.80% | 6.28% | 6.97% | 8.83% | 12.90% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-11 | REIDY, CHRISTOPHER R | Buy | 22,841 | — |
| 2026-02-11 | PRANGE, KAREN | Buy | 22,841 | — |
| 2026-02-11 | POMEROY, CLAIRE | Buy | 22,841 | — |
Peer comparison
Smart narrative
Embecta Corp trades at $3.90. representing a P/E of 3.92x trailing earnings. Our Smart Value Score of 56/100 indicates the stock is fair. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 1.56, it sits in the distress. TTM revenue stands at $1.08B. with profit margins at 12.90%. Our DCF model estimates intrinsic value at $46.96.
Frequently asked questions
What is Embecta Corp's stock price?
Embecta Corp (EMBC) trades at $3.90.
Is Embecta Corp overvalued?
Smart Value Score 56/100 (Grade C+, Hold). DCF value $46.96.
What is the price target of Embecta Corp (EMBC)?
The analyst target price is $15.00, representing +284.6% upside from the current price of $3.90.
What is the intrinsic value of Embecta Corp (EMBC)?
Based on our DCF model, intrinsic value is $46.96, a +78.6% margin of safety versus $3.90.
What is the future stock price of EMBC by 2030?
Our revenue-driven model estimates Embecta Corp could reach $8.81 by 2030, based on historical CAGR, margin trends, and capped P/E multiples.
What is Embecta Corp's revenue?
TTM revenue is $1.08B.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
1.56 — distress.
Company info
SectorHEALTHCARE
IndustryMEDICAL INSTRUMENTS & SUPPLIES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio0.51x
ROE—
Beta1.05
50D MA$9.24
200D MA$11.88
Shares out0.06B
Float0.06B
Short ratio—
Avg volume1.1M
Performance
1 week-57.38%
1 month-55.83%
3 months-62.75%
YTD-67.17%
1 year—
3 years—
5 years—